Related Experiment Video

Updated: Aug 18, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

[Oncogene expression in adriamycin and platinum resistant cell lines]

Y B Liu1

  • 1Department of Clinical Pharmacology, North Taiping Road Hospital, Beijing.

Zhonghua Yi Xue Za Zhi
|September 1, 1993
PubMed

Insights

Multidrug-resistant cancer cells show altered oncogene expression. Increased resistance correlates with poorer tumor multiplication potential and prognosis.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Context:

  • Investigating oncogene expression in drug-resistant cancer cell lines is crucial for understanding treatment resistance.
  • P388/ADR (doxorubicin-resistant) and L1210/cis-platinum resistant cell lines were used as models.
  • Sensitive cell lines (P388/0 and L1210/0) served as controls.

Purpose:

  • To analyze the expression levels of specific oncogenes (C-myc, v-erb-B, N-ras) in multidrug-resistant (MDR) cancer cell lines.
  • To determine the correlation between the degree of drug resistance and oncogene amplification.
  • To assess the prognostic implications of observed oncogene expression patterns in MDR cells.

Summary:

  • Dot hybridization revealed significant changes in C-myc, v-erb-B, and N-ras oncogene amplification in P388/ADR and L1210/cis-platinum resistant cells compared to sensitive counterparts.
  • Southern blot analysis indicated that oncogene amplification in these resistant cell lines remained unchanged.
  • A higher degree of multidrug resistance was associated with decreased oncogene amplification.

Impact:

  • The findings suggest that altered oncogene expression, specifically decreased amplification, in MDR cells may indicate a worse tumor multiplication potential.
  • This research highlights a potential link between specific oncogene expression patterns and tumor prognosis in the context of multidrug resistance.
  • These results could inform the development of novel therapeutic strategies targeting oncogene pathways in resistant cancers.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...